Sort
30,917 grants matching “tumor microenvironment”
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM
$393,773Irina V Balyasnikova · Northwestern University At Chicago · R01 · FY2023 · NS
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2021 · OD
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2021 · OD
Epithelial Cell Mechanobiology in Mechanically Heterogeneous Microenvironments
$393,750Amit Pathak · Washington University · R35 · FY2022 · GM
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2025 · OD
Epithelial Cell Mechanobiology in Mechanically Heterogeneous Microenvironments
$393,750Amit Pathak · Washington University · R35 · FY2021 · GM
DNA Damage as Women Age: Implications for Breast Cancer
$393,750Pacific Northwest Research Institute · R01 · FY2005 · AG
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2020 · OD
DNA Damage as Women Age: Implications for Breast Cancer
$393,750Pacific Northwest Research Institute · R01 · FY2003 · AG
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2023 · OD
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2022 · OD
DNA Damage as Women Age: Implications for Breast Cancer
$393,750Pacific Northwest Research Institute · R01 · FY2004 · AG
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2022 · OD
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2024 · OD
Validating the eCyPA/CD147 signaling complex for myeloma therapy
$393,715Ruben D Carrasco · Dana-Farber Cancer Inst · R01 · FY2015 · CA
Evolution and targeting of the functional states of glioblastoma
$393,604Anna Lasorella · University Of Miami School Of Medicine · R01 · FY2023 · CA
Mechanism regulating ErbB signaling network in head and neck cancer
$393,542Randall H Kramer · University Of California, San Francisco · R01 · FY2014 · DE
Project 2: Metabolism-Mediated Changes of Microvesicle Biogenesis
$393,515Richard A. Cerione · Cornell University · U54 · FY2016 · CA
Immune-inflammatory signaling and hormone-refractory prostate cancer evolution.
$393,505Jun-Li Luo · Scripps Research Institute, The · R01 · FY2014 · CA
The role and mechanism of necrosis in glioblastoma
$393,454Wei Li · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2021 · NS
The role and mechanism of necrosis in glioblastoma
$393,454Wei Li · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2023 · NS
The role and mechanism of necrosis in glioblastoma
$393,454Wei Li · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2022 · NS
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2018 · CA
Regulation of dendritic cell function and tumor immunity by TIM-3
$393,450Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2019 · CA
Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma Drug Resistance
$393,450Michaela R. Reagan · Mainehealth · R37 · FY2021 · CA